Cipla

  • Sensex at 10-day high, IT pack leads rally on TCS earnings 1 week ago

    Mumbai: The benchmark Sensex on Friday surged over 80 points to close at 25,641.56, its highest in 10 days, on sustained buying by foreign funds in IT shares after encouraging earnings from TCS. After opening in the negative zone and slipping further to 25,441.24 on profit-booking and a weak global cues...
  • Make essential drugs affordable for all: Cipla May 4, 2014

    New Delhi: Amid US firms' allegations of patent norm violations against Indian pharma companies, leading domestic drug maker Cipla has said that "essential" medicines be made available to people at affordable rates and should not be sold under "monopoly". "As a scientist I believe that an inventor or innovator of a...
  • Sensex ends 67 points up to end at record close March 5, 2014

    Mumbai: The benchmark Sensex on Wednesday extended gains by rising 67 points to end near its record close on sustained buying driven by positive global cues. Thawing of Ukraine crisis and upbeat economic data from China helped domestic markets, said traders. After gaining 263.08 points in the previous session, the Sensex...
  • Sensex surges nearly 257 points to end at 21,289.49 January 15, 2014

    Mumbai: All-round buying after wholesale inflation declined to a five-month low lifted the benchmark Sensex today by nearly 257 points to its highest level since December 9 on hopes the RBI will lower interest rate to boost economic growth. The NSE barometer Nifty also jumped over 79 points to reclaim the 6,300-point...
  • Shape up, or we'll ship out: India Inc to policymakers September 9, 2013

    After the rapid slide in the rupee this year, the message from the country's corporate titans to the government is clear: shape up and fix the problems or more companies will expand their business abroad and deprive the economy of investment. Many, such as entrepreneur Kiran Mazumdar-Shaw, are already doing just...
  • Novartis verdict will encourage genuine innovation: Prathiba M Singh April 3, 2013

    Prathiba M Singh, advocate for Ranbaxy and Cipla, fought the Glivec patent case against Novartis. She joined IBNLive readers for an interaction on the legal and moral compulsions behind this courtroom battle and the significance of the Supreme Court's decision for Indian pharma firms and the people of the country. Q....
  • Novartis stock down 4.5 per cent after SC verdict April 1, 2013

    Mumbai: Shares of the Swiss pharmaceutical giant Novartis fell about 4.5 per cent on Monday after the Supreme Court of India dismissed its plea for a patent on its cancer drug, Gelvic. Shares of select Indian pharmaceutical companies rallied as the industry is set to receive a boost following the...
  • Yusuf Hamied's message on being CNN-IBN's IOTY in business category December 17, 2012

    Dr. Yusuf K Hamied of Cipla Limited was awarded the CNN-IBN Indian of The Year 2012 in the business category. He was awarded for taking on multinational pharma companies and making some of the essential drugs more affordable to the masses in the developing countries. Here's Dr Hamid's message after being awarded...
  • Cipla appoints Subhanu Saxena as new CEO November 22, 2012

    Bangalore: Drug-maker Cipla on Thursday said it has appointed Subhanu Saxena as the Chief Executive Officer of the company. The appointment is effective from February 1, 2013. Saxena has more than 25 years of work experience. He has worked with companies such as Citicorp, The Boston Consulting Group and PepsiCo,...
  • Cipla launches HIV/AIDS treatment kit at Rs 158 August 14, 2012

    New Delhi: Drug major Cipla on Tuesday said it has launched 'Qvir', a four-drug kit priced at Rs 158 per kit to be used for treating HIV/AIDS. The kit consists of two tablets packaged together in one strip which represents a single day's treatment, Cipla said in a statement. Commenting on...
  • Drug safety norms being severely compromised May 14, 2012

    Mumbai: A Parliamentary committee has uncovered a nexus between doctors, government bodies and pharmacy companies to approve new drugs without the mandatory clinical trials. The doctors from top hospitals wrote to the country's Drug Controller General, to allow new drugs to be marketed, without clinical trials - a shocking lapse, highlighted...
  • Cancer drugs to cost less, Cipla slashes prices May 5, 2012

    Mumbai: After the Indian government recently lifted a patent license, Indian pharma major, Cipla, has announced a massive reduction of up to 76 per cent in its cancer drug prices. Following the move, the price of Cipla's generic kidney cancer drug, Sorafenib, will be available at Rs 6,840 a month from...
  • Pharma companies line up to bag Tamiflu contract August 13, 2009

    New Delhi: As the H1N1 Influenza virus (swine flu) death toll rises, pharma companies are lining to bag the contracts for Tamiflu. Five pharma companies are in the race as the government looks to procure close to 20 million Tamilflu capsules over the next few weeks. The drug is the only...
  • Anil Ambani group firms among top stock performers May 25, 2009

    Mumbai: Three companies in the Reliance Anil Dhirubhai Ambani Group were among the five top-performing stocks of the S&P CNX Nifty of the National Stock Exchange (NSE) last week, all of them outshining the 50-share index by a wide margin. With a gain of 52.7 per cent, Reliance Capital was the...
  • It's Congress vs Congress in Goa SEZ battle January 3, 2008

    New Delhi: The new twist in the Goa SEZ battle sees a case of odd politics: the Congress government in Goa is now at loggerheads with the Congress-led UPA at the Centre. Just days after Goa CM Digambar Kamat announced his decision to scrap the projected 15 SEZs in the...
  • India 360: TN fumes over 'morning after pill' ad August 22, 2007

    New Delhi: Cipla's new emergency contraceptive, popularly known as the 'morning after pill', the i-pill is showing contra-indications in Tamil Nadu. The Tamil Nadu Directorate of Drugs Control has sent a notice to a popular Tamil magazine, Ananda Vikatan, for publishing advertisements of the i-pill. ...
  • Bitter pill for Cipla, TN cracks down on contraceptive ad August 22, 2007

    Chennai: Cipla's new emergency contraceptive, popularly known as the 'morning after pill', the i-pill is showing contra-indications in Tamil Nadu. The Tamil Nadu Directorate of Drugs Control has sent a notice to a popular Tamil magazine, Ananda Vikatan, for publishing advertisements of the i-pill. Says Director Of Drugs Control, N...
  • India's own once-a-day AIDS drug October 14, 2006

    New Delhi:A breakthrough combination of three HIV/AIDS drugs, Viraday has been launched by Cipla which would help the HIV infected persons in effectively treating the dreaded disease by taking just one tablet a day. Viraday is a combination of three anti-HIV drugs including efavirenz 600 mg, tenofovir 300 mg and...